Immunology

A clinical trial of a correlate of risk targeted screen and treat strategy to impact TB control

Aims: Carry out a clinical trial and modelling of a correlate of risk targeted screen and treat strategy to impact TB control

People: Mark Hatherill (UCT), Tom Sumner, Gavin Churchyard (Aurum), Richard White, and colleagues

Funding: Bill and Melinda Gates Foundation


Modelling to accelerate TB vaccine candidate selection

Aims: Develop a framework in which mathematical models are used to better understand human and animal immune response to TB vaccination using available immunological data from the IC31 adjuvanted protein vaccine; Predict the best dose of the vaccine in terms of immunogenicity in humans based on varying dose-response data in animals

People: Sophie Rhodes, Tom Evans (Aeras), Steven Kern (BMGF), Gwen Knight (Imperial), Richard White, Helen Fletcher

Funding: Aeras


Empirical H56 TB vaccine dose ranging on mouse immunogenicity to inform mathematical modelling

Aims: Collect empirical data on H56 TB vaccine dose ranging on mouse immunogenicity to inform mathematical modelling

People: Sophie Rhodes, Tom Evans (Aeras), Steven Kern (BMGF), Gwen Knight (Imperial), Richard White, Helen Fletcher, and colleagues

Funding: Bill and Melinda Gates Foundation

Comments are closed.